Poxel (POXEL.PA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

POXEL.PA · Stock Price

EUR 0.25-0.11 (-30.94%)

Market Cap: $16.6M

Historical price data

Market Cap: $16.6MPipeline: 14 drugsFounded: 2021Employees: 50-100HQ: Lyon, France

Sector Ranking#333 in Small Molecule Drugs

Overview

Poxel is a French biotech focused on developing first-in-class treatments for metabolic diseases by targeting mitochondrial bioenergetics. Its strategy leverages two core platforms—direct AMPK activation and optimized thiazolidinediones (TZDs)—to build a pipeline led by mid-stage NASH candidates PXL065 and PXL770. The company has transitioned to a revenue-generating entity through royalties from its partnered drug, Imeglimin, in Japan, but operates under a court-validated financial recovery plan, highlighting significant capital constraints alongside its clinical progress.

Non-alcoholic Steatohepatitis (NASH)Rare Metabolic DisordersType 2 Diabetes

Technology Platform

Poxel leverages two core platforms: 1) Direct AMPK activation to restore cellular energy homeostasis, and 2) Optimized Thiazolidinediones (TZDs) using deuterium stabilization and enantiomer separation to improve drug profiles.

Pipeline

14

14 drugs in pipeline

Drug	Indication	Stage
Imeglimin + Placebo	Type 2 Diabetes Mellitus	Phase 2
PXL770	Adrenomyeloneuropathy	Phase 2
PXL770 + Placebo Oral Capsule	Nonalcoholic Fatty Liver	Phase 2
PXL065 + Placebo oral tablet	NASH - Nonalcoholic Steatohepatitis	Phase 2
PXL065	ALD (Adrenoleukodystrophy)	Phase 2

Funding History

4

Total raised:$155M

Debt$30MUndisclosedMay 15, 2019

IPO$60MUndisclosedJul 15, 2015

Series B$40MUndisclosedJun 15, 2013

Series A$25MUndisclosedJun 15, 2010

Opportunities

The $196M PXL770 sale provides critical capital to pursue a partnership for PXL065 in the vast, untapped NASH market.

Accelerating royalties from Imeglimin in Japan offer a stabilizing revenue stream.

Successful development of PXL065 could address a multi-billion dollar market with no approved pharmacotherapies.

Risk Factors

Extreme financial distress and shareholder dilution from the court-supervised continuation plan remain paramount.

PXL065 faces significant clinical development and regulatory risk in the competitive NASH landscape.

The company is now wholly dependent on securing a favorable partnership for its sole core asset.

Competitive Landscape

PXL065 competes in a crowded NASH field against large pharma and biotechs, including Madrigal's approved resmetirom and the looming presence of GLP-1 agonists. Poxel's severely constrained financial resources place it at a distinct disadvantage compared to well-capitalized peers, impacting its ability to independently develop and commercialize assets.